Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KALA BIO, Inc. SEC filings document the company's common stock, capital structure, governance, material agreements, listing status, and strategic transition from a clinical-stage biopharmaceutical issuer toward a dual biotech and AI infrastructure model. Recent Form 8-K disclosures cover the 1-for-50 reverse stock split, amendments to the certificate of incorporation, Nasdaq minimum-bid-price matters, and executive and board changes.
The filings also record material contracts and financing arrangements, including the Researgency platform development and exclusive license agreement, shelf-registration activity, at-the-market offering documents, and registered direct offering disclosures. Periodic and notice filings address annual-report timing, operating and financial reporting, risk factors, and the documentation needed for the company's evolving biologics pipeline and AI platform strategy.
Baker Bros. Advisors LP and affiliated filers report beneficial ownership of 744,759 shares of KALA BIO, Inc. common stock, representing 9.99% of the outstanding shares based on a 7,021,040 share base as of August 7, 2025 plus convertible preferred shares. The holdings include 434,200 shares issuable upon conversion of 4,342 Series E preferred shares; conversion of convertible preferred is subject to a 9.99% beneficial ownership limitation (increaseable to 19.99% with 61 days' notice). The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control; prior nomination rights under a purchase agreement were reported as no longer held as of October 2, 2025.
Baker Bros. reporting persons filed a Form 4 disclosing multiple sales of KALA BIO, Inc. (KALA) common stock on 09/30/2025 and 10/01/2025. The filing shows four separate dispositions: 21,376 and 195,425 shares on 09/30/2025 at a weighted average price of $1.5959, and 50,640 and 462,967 shares on 10/01/2025 at a weighted average price of $1.3838. After each reported transaction, the filings list the number of shares beneficially owned by the reporting entities and individuals on an indirect basis. Footnotes state the trading occurred through the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) across price ranges of $1.50–$1.84 and $1.27–$1.48, and clarify the Adviser and certain partners disclaim beneficial ownership except for pecuniary interest.
KALA BIO, Inc. filed an amended report to update details on previously announced cost-cutting measures and leadership retention plans. The board had decided on September 28, 2025 to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to reduce the workforce by approximately 19 employees, representing about 51% of staff.
The company now expects to incur about $0.4 million in costs related to the workforce reduction, mainly for severance and employee benefits, largely in the fourth quarter of 2025. On October 2, 2025, KALA BIO also entered into retention agreements with its President and CEO, CFO, and Head of R&D/CMO, providing retention payments of $183,750, $136,250, and $145,000, respectively, which must be repaid if they leave voluntarily or are terminated for cause before December 31, 2025.
KALA BIO, Inc. reported that its lender, Oxford Finance LLC, has delivered a written notice declaring an event of default under the companies’ Loan and Security Agreement. The notice states that the event of default is based on a contractual “Material Adverse Change” provision and alleges that additional defaults may exist.
As a result, Oxford has declared all obligations under the loan immediately due and payable and has started charging interest at the contractual default rate. The company reports that obligations accelerated and declared payable under the loan total $29.1 million, plus additional interest at the default rate and any expenses owed under the agreement.
KALA BIO, Inc. reported that its CHASE Phase 2b clinical trial of KPI-012 for treating persistent corneal epithelial defect did not meet its primary endpoint of complete healing and also failed to show statistically significant benefits on key secondary measures, with no meaningful difference versus placebo. Based on these results, the company plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform. To preserve cash while it evaluates strategic options, KALA’s board approved a workforce reduction of approximately 19 employees, or about 51%, expected to be substantially completed in the fourth quarter of 2025. The company has not yet determined the related accounting charges and plans to amend this report after it estimates them. KALA also plans to discuss its situation with its secured lender as part of its strategic review.
KALA BIO, Inc. has scheduled its 2025 annual meeting of stockholders for December 11, 2025. The company will provide the exact time, location and items to be voted on in its upcoming proxy statement for the meeting.
Stockholders who want to submit proposals for inclusion in the proxy materials under Rule 14a-8 must ensure the Company’s Secretary receives them at the Arlington, Massachusetts headquarters by October 1, 2025. Separately, stockholders who wish to nominate directors or bring other business at the meeting under the company’s Third Amended and Restated By-Laws must deliver notice by September 28, 2025, which is the tenth day after the public announcement of the meeting date.
KALA BIO, Inc. has scheduled its 2025 annual meeting of stockholders for December 11, 2025. The company will provide the exact time, location and items to be voted on in its upcoming proxy statement for the meeting.
Stockholders who want to submit proposals for inclusion in the proxy materials under Rule 14a-8 must ensure the Company’s Secretary receives them at the Arlington, Massachusetts headquarters by October 1, 2025. Separately, stockholders who wish to nominate directors or bring other business at the meeting under the company’s Third Amended and Restated By-Laws must deliver notice by September 28, 2025, which is the tenth day after the public announcement of the meeting date.
KALA BIO, Inc. Schedule 13G reports that Point72-related filers — Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen — jointly disclose beneficial ownership of 469,229 shares of KALA common stock, representing 6.7% of the class as of the close of business on September 10, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors exercise shared voting and dispositive power over these shares through Point72 Associates, an investment fund they manage. The filing includes a Joint Filing Agreement (Exhibit 99.1) and affirms the shares were not acquired to influence control of the issuer.
Perceptive Advisors and related parties report holding 543,745 shares of KALA BIO, Inc., representing 7.7% of the outstanding common stock. The Schedule 13G shows the Master Fund directly holds the shares and that Perceptive Advisors (as investment manager) and Joseph Edelman (managing member) may be deemed to beneficially own those shares. The filing states the position is held passively and not for the purpose of changing or influencing control of the issuer.
KALA BIO, Inc. reporting person Todd Bazemore, identified as a director and officer (President and Chief Executive Officer), was granted a stock option on 08/29/2025 to purchase 180,000 shares of common stock at an exercise price of $11.22 per share. The option vests over four years beginning on the vesting commencement date of 08/29/2025, with 1/48th of the shares vesting at the end of each successive one-month period until 08/29/2029, subject to continued service. The option lists an expiration/exercisable date of 08/28/2035. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.
KALA BIO, Inc. appointed Todd Bazemore as Chief Executive Officer, effective immediately, while he continues as President and leaves the Chief Operating Officer role. He was also elected as a Class II director, serving until the 2025 annual stockholders’ meeting or earlier departure.
The company amended his offer letter to set an annual base salary of $655,000 and a target annual bonus equal to 60% of base salary. Following a qualifying termination within 24 months after a change of control, he may receive 24 months of salary, certain bonus amounts, 24 months of COBRA premiums, and outplacement services. He also received an option to purchase 180,000 shares of common stock at the Effective Date’s closing price, vesting monthly over four years, subject to continued service.